Veracyte (VCYT) Current Deferred Revenue (2016 - 2025)
Historic Current Deferred Revenue for Veracyte (VCYT) over the last 12 years, with Q3 2025 value amounting to $417000.0.
- Veracyte's Current Deferred Revenue fell 7948.84% to $417000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $417000.0, marking a year-over-year decrease of 7948.84%. This contributed to the annual value of $1.7 million for FY2024, which is 1668.33% down from last year.
- Latest data reveals that Veracyte reported Current Deferred Revenue of $417000.0 as of Q3 2025, which was down 7948.84% from $1.4 million recorded in Q2 2025.
- In the past 5 years, Veracyte's Current Deferred Revenue ranged from a high of $4.9 million in Q1 2022 and a low of $417000.0 during Q3 2025
- In the last 5 years, Veracyte's Current Deferred Revenue had a median value of $2.2 million in 2024 and averaged $2.4 million.
- Per our database at Business Quant, Veracyte's Current Deferred Revenue soared by 115229.11% in 2021 and then crashed by 7948.84% in 2025.
- Quarter analysis of 5 years shows Veracyte's Current Deferred Revenue stood at $4.6 million in 2021, then crashed by 43.76% to $2.6 million in 2022, then dropped by 23.15% to $2.0 million in 2023, then dropped by 16.68% to $1.7 million in 2024, then plummeted by 75.07% to $417000.0 in 2025.
- Its last three reported values are $417000.0 in Q3 2025, $1.4 million for Q2 2025, and $1.7 million during Q1 2025.